Skip to main content
Erschienen in: European Radiology 4/2022

13.10.2021 | Hepatobiliary-Pancreas

Prediction of recurrence after surgery based on preoperative MRI features in patients with pancreatic neuroendocrine tumors

verfasst von: Seungchul Han, Jung Hoon Kim, Jeongin Yoo, Siwon Jang

Erschienen in: European Radiology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To investigate useful MRI features in pancreatic neuroendocrine tumor (PNET) patients for predicting recurrence and its timing after surgery.

Methods

A total of 99 patients with PNET who underwent MRI and surgery from 2000 to 2018 were enrolled. Two radiologists independently assessed MRI findings, including size, location, margin, T1 and T2 signal intensity, enhancement patterns, common bile duct (CBD) or main pancreatic duct (MPD) dilatation, vascular invasion, lymph node enlargement, DWI, and ADC value. Imaging findings associated with recurrence and disease-free survival (DFS) were assessed using logistic regression analysis and Cox proportional hazard regression analysis.

Results

The median follow-up period was 40.4 months, and recurrence after surgery occurred in 12.1% (12/99). Among them, 6 patients experienced recurrence within 1 year, and 9 patients experienced recurrence within 2 years after surgery. In multivariate analysis, major venous invasion (OR 10.76 [1.14–101.85], p = 0.04) was associated with recurrence within 1 year, and portal phase iso- to hypoenhancement (OR 51.89 [1.73–1557.89], p = 0.02), CBD or MPD dilatation (OR 10.49 [1.35–81.64], p = 0.03) and larger size (OR 1.05 [1.00–1.10], p = 0.046) were associated with recurrence within 2 years. The mean DFS was 116.4 ± 18.5 months, and the 5-year DFS rate was 85.7%. In multivariate analysis, portal phase iso- to hypoenhancement (HR 21.36 [2.01–197.77], p = 0.01), ductal dilatation (HR 5.22 [1.46–18.68], p = 0.01), major arterial invasion (HR 42.90 [3.66–502.48], p = 0.003), and larger size (HR 1.04 [1.01–1.06], p = 0.01) showed a significant effect on poor DFS.

Conclusion

MRI features, including size, enhancement pattern, vascular invasion, and ductal dilatation, are useful in predicting recurrence and poor DFS after surgery in PNET.
Key Points
MRI features are useful for predicting prognosis in patients with PNET after surgery.
PV or SMV invasion (OR 10.49 [1.35–81.64], p = 0.04) was significantly associated with 1-year recurrence.
Portal phase iso- to hypoenhancement (HR 21.36), CBD or MPD dilatation (HR 5.22), arterial invasion (HR 42.90), and larger size (HR 1.04) had significant effects on poor DFS (p < 0.05).
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Fraenkel M, Kim MK, Faggiano A, Valk GD (2012) Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 26:691–703CrossRef Fraenkel M, Kim MK, Faggiano A, Valk GD (2012) Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 26:691–703CrossRef
2.
Zurück zum Zitat Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM (2011) The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40(1–18):vii Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM (2011) The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40(1–18):vii
3.
Zurück zum Zitat Dasari A, Shen C, Halperin D et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3:1335–1342CrossRef Dasari A, Shen C, Halperin D et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3:1335–1342CrossRef
4.
Zurück zum Zitat Shah M, Goldner W, Halfdanarson T et al (2018) NCCN clinical practice guidelines in oncology: neuroendocrine and adrenal tumors. J Natl Compr Cancer Netw 16:693–702CrossRef Shah M, Goldner W, Halfdanarson T et al (2018) NCCN clinical practice guidelines in oncology: neuroendocrine and adrenal tumors. J Natl Compr Cancer Netw 16:693–702CrossRef
5.
Zurück zum Zitat Kunz PL, Reidy-Lagunes D, Anthony LB et al (2013) Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 42:557–577CrossRef Kunz PL, Reidy-Lagunes D, Anthony LB et al (2013) Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 42:557–577CrossRef
6.
Zurück zum Zitat Rindi G, Falconi M, Klersy C et al (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104:764–777CrossRef Rindi G, Falconi M, Klersy C et al (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104:764–777CrossRef
7.
Zurück zum Zitat Genç CG, Falconi M, Partelli S et al (2018) Recurrence of pancreatic neuroendocrine tumors and survival predicted by Ki67. Ann Surg Oncol 25:2467–2474CrossRef Genç CG, Falconi M, Partelli S et al (2018) Recurrence of pancreatic neuroendocrine tumors and survival predicted by Ki67. Ann Surg Oncol 25:2467–2474CrossRef
8.
Zurück zum Zitat Kim H, Song KB, Hwang DW, Lee JH, Alshammary S, Kim SC (2019) Time-trend and recurrence analysis of pancreatic neuroendocrine tumors. Endocr Connect 8:1052–1060CrossRef Kim H, Song KB, Hwang DW, Lee JH, Alshammary S, Kim SC (2019) Time-trend and recurrence analysis of pancreatic neuroendocrine tumors. Endocr Connect 8:1052–1060CrossRef
9.
Zurück zum Zitat Canellas R, Lo G, Bhowmik S, Ferrone C, Sahani D (2018) Pancreatic neuroendocrine tumor: correlations between MRI features, tumor biology, and clinical outcome after surgery. J Magn Reson Imaging 47:425–432CrossRef Canellas R, Lo G, Bhowmik S, Ferrone C, Sahani D (2018) Pancreatic neuroendocrine tumor: correlations between MRI features, tumor biology, and clinical outcome after surgery. J Magn Reson Imaging 47:425–432CrossRef
10.
Zurück zum Zitat Guo C, Chen X, Xiao W, Wang Q, Sun K, Wang Z (2017) Pancreatic neuroendocrine neoplasms at magnetic resonance imaging: comparison between grade 3 and grade 1/2 tumors. Onco Targets Ther 10:1465–1474CrossRef Guo C, Chen X, Xiao W, Wang Q, Sun K, Wang Z (2017) Pancreatic neuroendocrine neoplasms at magnetic resonance imaging: comparison between grade 3 and grade 1/2 tumors. Onco Targets Ther 10:1465–1474CrossRef
12.
Zurück zum Zitat Takumi K, Fukukura Y, Higashi M et al (2015) Pancreatic neuroendocrine tumors: correlation between the contrast-enhanced computed tomography features and the pathological tumor grade. Eur J Radiol 84:1436–1443CrossRef Takumi K, Fukukura Y, Higashi M et al (2015) Pancreatic neuroendocrine tumors: correlation between the contrast-enhanced computed tomography features and the pathological tumor grade. Eur J Radiol 84:1436–1443CrossRef
13.
Zurück zum Zitat Toshima F, Inoue D, Komori T et al (2017) Is the combination of MR and CT findings useful in determining the tumor grade of pancreatic neuroendocrine tumors? Jpn J Radiol 35:242–253CrossRef Toshima F, Inoue D, Komori T et al (2017) Is the combination of MR and CT findings useful in determining the tumor grade of pancreatic neuroendocrine tumors? Jpn J Radiol 35:242–253CrossRef
14.
Zurück zum Zitat Kim DW, Kim DW, Kim HJ et al (2015) Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT: comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour. Eur Radiol 25:1375–1383CrossRef Kim DW, Kim DW, Kim HJ et al (2015) Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT: comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour. Eur Radiol 25:1375–1383CrossRef
15.
Zurück zum Zitat Lewis RB, Lattin GE Jr, Paal E (2010) Pancreatic endocrine tumors: radiologic-clinicopathologic correlation. Radiographics 30:1445–1464CrossRef Lewis RB, Lattin GE Jr, Paal E (2010) Pancreatic endocrine tumors: radiologic-clinicopathologic correlation. Radiographics 30:1445–1464CrossRef
16.
Zurück zum Zitat d’Assignies G, Couvelard A, Bahrami S et al (2009) Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors d’Assignies G, Couvelard A, Bahrami S et al (2009) Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors
17.
Zurück zum Zitat Kim JH, Eun HW, Kim YJ, Lee JM, Han JK, Choi BI (2016) Pancreatic neuroendocrine tumour (PNET): staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma. Eur Radiol 26:1338–1347CrossRef Kim JH, Eun HW, Kim YJ, Lee JM, Han JK, Choi BI (2016) Pancreatic neuroendocrine tumour (PNET): staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma. Eur Radiol 26:1338–1347CrossRef
18.
Zurück zum Zitat Worhunsky DJ, Krampitz GW, Poullos PD et al (2014) Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. HPB (Oxford) 16:304–311CrossRef Worhunsky DJ, Krampitz GW, Poullos PD et al (2014) Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. HPB (Oxford) 16:304–311CrossRef
19.
Zurück zum Zitat Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRef Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRef
21.
Zurück zum Zitat Kawamoto S, Shi C, Hruban RH et al (2011) Small serotonin-producing neuroendocrine tumor of the pancreas associated with pancreatic duct obstruction. AJR Am J Roentgenol 197:W482-488CrossRef Kawamoto S, Shi C, Hruban RH et al (2011) Small serotonin-producing neuroendocrine tumor of the pancreas associated with pancreatic duct obstruction. AJR Am J Roentgenol 197:W482-488CrossRef
22.
Zurück zum Zitat Zandee WT, van Adrichem RC, Kamp K, Feelders RA, van Velthuysen MF, de Herder WW (2017) Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours. Clin Endocrinol (Oxf) 87:165–170CrossRef Zandee WT, van Adrichem RC, Kamp K, Feelders RA, van Velthuysen MF, de Herder WW (2017) Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours. Clin Endocrinol (Oxf) 87:165–170CrossRef
23.
Zurück zum Zitat Kim C, Byun JH, Hong SM et al (2017) A comparison of enhancement patterns on dynamic enhanced CT and survival between patients with pancreatic neuroendocrine tumors with and without intratumoral fibrosis. Abdom Radiol (NY) 42:2835–2842CrossRef Kim C, Byun JH, Hong SM et al (2017) A comparison of enhancement patterns on dynamic enhanced CT and survival between patients with pancreatic neuroendocrine tumors with and without intratumoral fibrosis. Abdom Radiol (NY) 42:2835–2842CrossRef
24.
Zurück zum Zitat Marion-Audibert AM, Barel C, Gouysse G et al (2003) Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 125:1094–1104CrossRef Marion-Audibert AM, Barel C, Gouysse G et al (2003) Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 125:1094–1104CrossRef
25.
Zurück zum Zitat Rodallec M, Vilgrain V, Couvelard A et al (2006) Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology 6:77–85CrossRef Rodallec M, Vilgrain V, Couvelard A et al (2006) Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology 6:77–85CrossRef
26.
Zurück zum Zitat Guo C, Zhuge X, Chen X, Wang Z, Xiao W, Wang Q (2017) Value of diffusion-weighted magnetic resonance imaging in predicting World Health Organization grade in G1/G2 pancreatic neuroendocrine tumors. Oncol Lett 13:4141–4146CrossRef Guo C, Zhuge X, Chen X, Wang Z, Xiao W, Wang Q (2017) Value of diffusion-weighted magnetic resonance imaging in predicting World Health Organization grade in G1/G2 pancreatic neuroendocrine tumors. Oncol Lett 13:4141–4146CrossRef
27.
Zurück zum Zitat Bettini R, Partelli S, Boninsegna L et al (2011) Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery 150:75–82CrossRef Bettini R, Partelli S, Boninsegna L et al (2011) Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery 150:75–82CrossRef
28.
Zurück zum Zitat Manfredi R, Bonatti M, Mantovani W et al (2013) Non-hyperfunctioning neuroendocrine tumours of the pancreas: MR imaging appearance and correlation with their biological behaviour. Eur Radiol 23:3029–3039CrossRef Manfredi R, Bonatti M, Mantovani W et al (2013) Non-hyperfunctioning neuroendocrine tumours of the pancreas: MR imaging appearance and correlation with their biological behaviour. Eur Radiol 23:3029–3039CrossRef
29.
Zurück zum Zitat Canellas R, Burk KS, Parakh A, Sahani DV (2018) Prediction of pancreatic neuroendocrine tumor grade based on CT features and texture analysis. AJR Am J Roentgenol 210:341–346CrossRef Canellas R, Burk KS, Parakh A, Sahani DV (2018) Prediction of pancreatic neuroendocrine tumor grade based on CT features and texture analysis. AJR Am J Roentgenol 210:341–346CrossRef
30.
Zurück zum Zitat Chun YS, Pawlik TM, Vauthey JN (2018) 8th edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers. Ann Surg Oncol 25:845–847CrossRef Chun YS, Pawlik TM, Vauthey JN (2018) 8th edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers. Ann Surg Oncol 25:845–847CrossRef
31.
Zurück zum Zitat Rindi G (2010) The ENETS guidelines: the new TNM classification system. Tumori 96:806–809CrossRef Rindi G (2010) The ENETS guidelines: the new TNM classification system. Tumori 96:806–809CrossRef
Metadaten
Titel
Prediction of recurrence after surgery based on preoperative MRI features in patients with pancreatic neuroendocrine tumors
verfasst von
Seungchul Han
Jung Hoon Kim
Jeongin Yoo
Siwon Jang
Publikationsdatum
13.10.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 4/2022
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-021-08316-8

Weitere Artikel der Ausgabe 4/2022

European Radiology 4/2022 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.